Clinical significance of peripheral zone thickness in men with lower urinary tract symptoms/benign prostatic hyperplasia Jong Kyou Kwon, Jang Hee Han*, Ho Chul Choi*, Dong Hyuk Kang†, Joo Yong Lee*, Jae Heon Kim‡, Cheol Kyu Oh, Young Deuk Choi* and Kang Su Cho* Department of Urology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, *Department of Urology, Gangnam Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, ‡Department of Urology, Sooncheonhyang University Hospital, Suncheonhyang University College of Medicine, Seoul, and † Department of Urology, Yangpyeong Health Center, Yangpyeong, Korea
Objective To evaluate the clinical impact of prostate peripheral zone thickness (PZT), based on presumed circle area ratio (PCAR) theory, on urinary symptoms in men with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) as a novel prostate parameter.
Patients and methods Medical records were obtained from a prospective database of first-visit men with LUTS/BPH. Age, international prostate symptom score (IPSS), overactive bladder symptom score (OABSS), maximum urinary flow rate (Qmax), and post-void residual urine volume (PVR) were assessed. Total prostate volume (TPV), transition zone volume (TZV), transition zone index (TZI), and PZT were measured by transrectal ultrasonography. Reliability analysis was also performed.
into three groups PZT thickness groups; PZT d”
C
–0 D
© 2015 The Authors BJU International © 2015 BJU International
317
Kwon et al.
calculations and comparisons. For greater accuracy, two investigators (J.K.K. and J.H.H.) measured PZT independently and the average of their two values was used for the analyses.
patients with large prostatic calcification that hindered exact PZT measurement, three patients with huge prostates that had indefinite prostatic outer margins, and two patients with abdominal ultrasound measurements.
Assessment of LUTS
In all, 1009 patients were enrolled for analyses. The mean (SD) age was 62.0 (10.0) years and the median (interquartile range, IQR) PSA level was 1.18 (0.64–2.53) ng/mL. The mean (SD) IPSS was 16.7 (7.5) points, and the mean (SD) TPV and TZV were 33.3 (16.2) mL and 16.0 (11.5) mL, respectively. The median (IQR) TZI was 0.45 (0.39–0.52) and the mean (SD) PZT was 11.10 (2.50) mm (Table 1). The PZT values obtained by the two independent examiners were in excellent agreement with an ICC of 0.896 (95% CI 0.883–0.908).
Urinary symptom scores were evaluated using the IPSS, quality of life (QoL) score, and the Overactive Bladder Symptom Score (OABSS) questionnaires. Uroflowmetry measurements, e.g. Qmax and post-void residual urine volume (PVR), were performed using Bluetooth uroflowmetry, (Urodyn+; Mediwatch UK, Ltd., Ruby, UK), with the patient in the standing position. If the voided volume was
Objective To evaluate the clinical impact of prostate peripheral zone thickness (PZT), based on presumed circle area ratio (PCAR) theory, on urinary symptoms in men with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) as a novel prostate parameter.
Patients and methods Medical records were obtained from a prospective database of first-visit men with LUTS/BPH. Age, international prostate symptom score (IPSS), overactive bladder symptom score (OABSS), maximum urinary flow rate (Qmax), and post-void residual urine volume (PVR) were assessed. Total prostate volume (TPV), transition zone volume (TZV), transition zone index (TZI), and PZT were measured by transrectal ultrasonography. Reliability analysis was also performed.
into three groups PZT thickness groups; PZT d”
C
–0 D
© 2015 The Authors BJU International © 2015 BJU International
317
Kwon et al.
calculations and comparisons. For greater accuracy, two investigators (J.K.K. and J.H.H.) measured PZT independently and the average of their two values was used for the analyses.
patients with large prostatic calcification that hindered exact PZT measurement, three patients with huge prostates that had indefinite prostatic outer margins, and two patients with abdominal ultrasound measurements.
Assessment of LUTS
In all, 1009 patients were enrolled for analyses. The mean (SD) age was 62.0 (10.0) years and the median (interquartile range, IQR) PSA level was 1.18 (0.64–2.53) ng/mL. The mean (SD) IPSS was 16.7 (7.5) points, and the mean (SD) TPV and TZV were 33.3 (16.2) mL and 16.0 (11.5) mL, respectively. The median (IQR) TZI was 0.45 (0.39–0.52) and the mean (SD) PZT was 11.10 (2.50) mm (Table 1). The PZT values obtained by the two independent examiners were in excellent agreement with an ICC of 0.896 (95% CI 0.883–0.908).
Urinary symptom scores were evaluated using the IPSS, quality of life (QoL) score, and the Overactive Bladder Symptom Score (OABSS) questionnaires. Uroflowmetry measurements, e.g. Qmax and post-void residual urine volume (PVR), were performed using Bluetooth uroflowmetry, (Urodyn+; Mediwatch UK, Ltd., Ruby, UK), with the patient in the standing position. If the voided volume was
